Curative Biotechnology IncOTC Pink - Current Information:CUBT
- LAST PRICE0.0086
- TODAY'S CHANGE (%)-0.0001 (-0.9770%)
- Bid / Lots0.0070/ 250
- Ask / Lots0.0087/ 100
- Open / Previous Close0.0076 / 0.0087
- Day Range
- 52 Week Range
- Volume50,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CUBT |
|---|---|---|
| 10:22 ET | 10000 | 0.0076 |
| 03:37 ET | 5000 | 0.0087 |
| 03:42 ET | 15000 | 0.00785 |
| 03:44 ET | 10000 | 0.00785 |
| 03:46 ET | 10000 | 0.008615 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Curative Biotechnology Inc | 7.9M | -0.8x | --- |
Moleculin Biotech Inc | 8.2M | -0.2x | --- |
Cardio Diagnostics Holdings Inc | 8.1M | -0.7x | --- |
Bioxytran Inc | 8.2M | -4.9x | --- |
Vincerx Pharma Inc | 7.5M | -0.2x | --- |
Galecto Inc | 7.4M | -0.3x | --- |
Company Information
Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. It is primarily focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its development pipeline is focused on three therapeutic areas: infectious diseases, oncology, and degenerative eye disease. Under these therapeutic areas, it has targeted three programs: Rabies, Glioblastoma, and Degenerative Eye Diseases. IMT504 is a synthetic immunotherapy to treat late-stage rabies as a stand-alone therapy.
Contact Information
- Headquarters
- 1825 Nw Corporate Blvd., Suite 110BOCA RATON, FL, United States 33431
- Phone
- 561-907-8990
- Fax
- ---
Executives
- Chairman of the Board, President
- Paul Michaels
- Chief Executive Officer, Chief Financial Officer, General Counsel
- Richard Garr
- Director
- Michael Fish
- Director, Chief Strategy Officer
- Barry Ginsberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 903.3M |
Curative Biotechnology Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.00 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
